SCHEMBL6841691

SCHEMBL6841691

COC(=O)[C@H]1C=C[C@@H](NC(C)=O)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MMP2 P08253 3/20 0.34
ANPEP P15144 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CHRNB2 P17787 2/20 0.32
CHRNA4 P43681 2/20 0.32
ATM Q13315 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA7 P36544 1/20 0.32
MTNR1A P48039 2/20 0.31
MTNR1B P49286 1/20 0.31
TSHR P16473 1/20 0.31
NAE1 Q13564 1/20 0.30
UBA3 Q8TBC4 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8893825 1.00 CYP1A2 (0.35) CYP1A2CYP2C19HSD17B10MMP2ANPEP
SCHEMBL10357493 1.00 CYP1A2 (0.35) CYP1A2CYP2C19HSD17B10MMP2ANPEP
SCHEMBL6836198 0.84 NFKB1 (0.39) HSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL6836199 0.84 NFKB1 (0.39) HSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL6917661 0.84 NFKB1 (0.39) HSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL6841531 0.82 ALDH1A1 (0.35) SMN1; SMN2NPSR1TSHRKDM4EALDH1A1
SCHEMBL6841385 0.82 ALDH1A1 (0.35) SMN1; SMN2NPSR1TSHRKDM4EALDH1A1
SCHEMBL14199306 0.81 CHRNB2 (0.33) CYP1A2HSD17B10MMP2ANPEPCHRNB2
SCHEMBL25600138 0.81 CHRNB2 (0.33) CYP1A2HSD17B10MMP2ANPEPCHRNB2
SCHEMBL6840860 0.81 SMN1; SMN2 (0.37) SMN1; SMN2NPSR1ATMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040167351-A1 Method for preparing (1R,4S)-2-azabicyclo[2.2.1]hept-5-ene-3-one derivatives BERNEGGER-EGLI CHRISTINE (CH) 2004-08-26 US disclosed
EP-0349242-B1 Therapeutic nucleosides WELLCOME FOUND (GB) 1995-03-22 EP disclosed
EP-0424064-B1 Chiral azabicyloheptanone and a process for their preparation CHIROSCIENCE LTD (GB) 1995-02-08 EP disclosed
EP-0393499-A1 Process for preparing carbovir and new intermediate products therefor F. HOFFMANN-LA ROCHE AG (CH) 1990-10-24 EP disclosed
US-4939252-A Novel intermediates for the preparation of Carbovir HOFFMANN-LA ROCHE INC. (US) 1990-07-03 US disclosed
EP-0349242-A2 Therapeutic nucleosides THE WELLCOME FOUNDATION LIMITED (GB) 1990-01-03 EP disclosed
US-4383114-A ANTITUMOR AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1983-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167351-A1 Method for preparing (1R,4S)-2-azabicyclo[2.2.1]hept-5-ene-3-one derivatives APEH, CYP51A1, CYP8B1 CYP1A2 26/4885CYP2C19 195/4885HSD17B10 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.